Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor.
Current urology(2021)
摘要
Sarcomatoid differentiation, hypercalcemia, an elevated serum CRP level, and presence of liver metastasis were associated with primary refractory disease in mRCC patients receiving first-line TKI therapy. These results provide clinicians with useful information when selecting a first-line therapeutic option for mRCC patients.
更多查看译文
关键词
Metastatic renal cell carcinoma,Overall survival,Predictive factor,Tyrosine kinase inhibitor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要